{"url_path":"/sec/irwd/8-k/2026-06-15/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-15","source_url":"https://www.sec.gov/Archives/edgar/data/1446847/0001104659-26-074023-index.html","accession_number":"0001104659-26-074023","cik":"0001446847","ticker":"IRWD","issuer_name":"IRONWOOD PHARMACEUTICALS INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1446847/0001104659-26-074023-index.html","primary_entity_key":"0001446847","primary_entity_name":"IRONWOOD PHARMACEUTICALS INC"},"word_count":146,"has_tables":true,"body_markdown":"**Item 8.01 Other Events.**\n\n \n\nOn June 15, 2026, Ironwood Pharmaceuticals, Inc.\n(the “Company”) repaid in full the $200.0 million aggregate principal amount of its 1.50% convertible senior notes due 2026\n(the “2026 Convertible Notes”) at their scheduled maturity. The Company funded the repayment of the outstanding aggregate\nprincipal amount of the 2026 Convertible Notes using proceeds from available cash on hand. No conversions were exercised by holders of\nthe 2026 Convertible Notes, and the capped call transactions the Company has separately entered into in connection with the issuance\nof the 2026 Convertible Notes terminated upon expiry.\n\n \n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities\nExchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n**Ironwood Pharmaceuticals, Inc.**\n\n \n \n \n\nDated: June 15, 2026\nBy:\n/s/ Ronald Silver\n\n \n \nName: Ronald Silver\n\n \n \nTitle: Interim Chief Financial Officer"}